Lumida
/KALV
⌘K
Kalvista Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

KALV
$27.00USD↑+0.04%+0.01 today

MARKET CAP

1.4B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$27 – $27

52W RANGE

$10
$27

AI Summary

Stalk
StalkMedium

KALV remains in a Stage 2 advancing regime underpinned by a strong parabolic acceleration, reinforcing a bullish medium-term bias. However, price is severely extended above rising short-term EMAs with RSI and Options Score in extreme overbought territory, signaling near-term exhaustion risk. Execution should be deferred and staged on meaningful pullbacks into the rising EMA zone or the recent breakout support area.

  • ↑Ectorly launch generated $1.4M net revenue in Q1, capturing 5% of U.S. HAE prescriptions
  • ↑FDA-approved oral on-demand therapy with pediatric NDA filing planned after positive Phase 3 interim data
  • ↓Q1 operating expenses totalled $60.4M, including $15M in R&D and SG&A costs
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

KalVista Pharmaceuticals (NASDAQ:KALV) is a biopharmaceutical company specializing in innovative therapies for hereditary angioedema (HAE). With its lead product, Ectorly, being the first and only oral on-demand therapy for acute HAE attacks, KalVista has positioned itself as a transformative player in the rare disease landscape. Following its recent acquisition by Chiesi Group, KalVista now operates as part of Chiesi's Rare Diseases unit, enabling further resources and focus on growth within the high-demand specialty pharmaceuticals market.

Bull says

  • ↑Ectorly launch generated $1.4M net revenue in Q1, capturing 5% of U.S. HAE prescriptions
  • ↑FDA-approved oral on-demand therapy with pediatric NDA filing planned after positive Phase 3 interim data
  • ↑Acquisition by Chiesi Group brings $191M cash runway and global commercialization support
  • ↑High earnings yield, strong momentum factors, and robust free-cash-flow/EV ratio signal attractive valuation
  • ↑Pipeline upside from KONFIDENT-KID pediatric study and pending international approvals

Bear says

  • ↓Q1 operating expenses totalled $60.4M, including $15M in R&D and SG&A costs
  • ↓Payer coverage often lags six months, hindering timely patient access
  • ↓Seasonal fluctuations risk normalizing early prescription momentum
  • ↓Negative leverage and profitability scores indicate balance sheet and margin pressure
  • ↓High short interest reflects investor skepticism on scaling and reimbursement

Investment themes with KALV

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 04-29-2026neutral

Transcript signals

Bull points

  • We are highly encouraged by Ectoly's first three months on the U.S. market. Adoption has been steady and linear with real world utilization tracking as we expected. The takeaways are clear. Demand for Ecterly is strong. It is being used to treat a significant number of HAE attacks, and it is meeting the expectations of people living with HAE for a highly efficacious and safe therapeutic alternative.
  • We continue to believe that Ecterly will evolve to become the foundational treatment for HAE.
  • In addition, We are executing on our mission to bring Ectoly to people living with HAE globally.

Bear points

  • When looking at gross to net, I'd note it came in towards the low end of our expected range this quarter, driven largely by lower copay utilization typical for this time of year.
  • total operating expenses for the period were $59.7 million, consisting of approximately $12 million in RDA expenses and approximately $46.5 million in SG&A expenses.
  • we are planning to, I would say, wrap up discussions with some of the larger payers in PBMs. with an aim to have policies in place, again, early in 2026.
Read full transcript analysis ›